▲ Human lifespan evidence: no healthy-aging lifespan RCT — imetelstat is a telomerase INHIBITOR approved for a disease (lower-risk MDS); it is the opposite direction from anti-aging telomerase activation and is not an aging therapy

Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase is silenced in most somatic cells and reactivated in most cancers, so its activation raises an unresolved cancer-risk question. Tellingly, the only FDA-approved telomerase drug — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.

What it is

Class: Oligonucleotide telomerase inhibitor (cancer drug) — the honesty foil

Also known as: imetelstat, GRN163L, RYTELO

Relationship to telomere biology: Imetelstat is a lipid-conjugated oligonucleotide that binds the RNA template of telomerase (TERC) and INHIBITS the enzyme. It is included here deliberately as the honesty foil: the only FDA-approved telomerase drug points in the OPPOSITE direction from anti-aging 'activation' — it shuts telomerase down to treat cancer.

Regulatory status

FDA-approved in June 2024 as RYTELO for transfusion-dependent anemia in adults with lower-risk myelodysplastic syndromes (MDS). This is a cancer/hematology approval for a telomerase INHIBITOR — it is NOT an anti-aging drug and is the opposite mechanism from telomerase activation.

Mechanism

By inhibiting telomerase, imetelstat preferentially depletes the malignant clones in MDS/myelofibrosis that depend on telomerase. In the IMerge Phase 3 trial it improved red-cell transfusion independence versus placebo. This is why the field's only approved telomerase drug treats cancer by SUPPRESSING the enzyme. See /telomerase-cancer-paradox.

Evidence — Human (Phase 3 RCT — disease population)

Species / population	Adults with transfusion-dependent, ESA relapsed/refractory IPSS low or intermediate-1 risk MDS (IMerge Phase 3, NCT02598661; enrolment 289).
Exposure, route, schedule	Intravenous imetelstat every 4 weeks.
Comparator / duration	Randomized, double-blind, placebo-controlled.
Endpoint / numeric result	Higher rate of durable (≥8-week and ≥24-week) red-cell transfusion independence versus placebo, supporting the 2024 FDA approval.
What it did NOT establish	This is cancer/hematology treatment via telomerase INHIBITION in a disease population. It is not an aging trial, and it is the opposite mechanistic direction from the 'telomerase activation' anti-aging narrative.

Negative or null findings

Imetelstat is an INHIBITOR, not an activator — reading it as a 'telomerase longevity drug' inverts its actual mechanism and indication.
It carries significant hematologic toxicity (cytopenias); it is a disease treatment, not a wellness intervention.

Studies on this page

IMerge Phase 3: imetelstat (telomerase INHIBITOR) in lower-risk MDS (Platzbecker et al., 2024)

Imetelstat (telomerase INHIBITOR)